Zepbound for Teens: No FDA Pediatric Dose Yet

Editorial evidence status: This page was reconciled to the February 2026 FDA label, ClinicalTrials.gov, and published pediatric tirzepatide evidence on August 29, 2026. Medical review is pending. It explains the evidence boundary; it does not provide an off-label pediatric dose or decide treatment for a child.

The Direct Answer: There Is No FDA-Approved Teen Dose

The current Zepbound label limits its weight-reduction and obstructive-sleep-apnea indications to adults [1]. Section 8.4 states: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients" [1]. That short regulator statement is the controlling boundary, not an endorsement, prohibition on all clinician judgment, or claim that ongoing research will fail.

The label's 2.5 mg initiation, 2.5 mg escalation steps, and 5, 10, or 15 mg weight-management maintenance doses appear inside the adult prescribing information [1]. Copying that ladder into a page titled "adolescent dosing" converts adult instructions into an unsupported pediatric protocol. The label also supplies no 60 kg minimum, BMI-z response threshold, mandatory laboratory panel, or teen-specific maximum dose.

Age 18 therefore changes the evidence category. It does not mean every 18-year-old was separately studied, and it does not make the young-adult safety question identical to the under-18 question. Adults 18 to 29 fall within the labeled age range; adolescents do not.

Adolescent Tirzepatide Evidence Boundary Map

This map separates "there is pediatric tirzepatide research" from "there is an FDA-approved Zepbound teen dose." They are not the same claim.

What the Adolescent Obesity Trial Can Tell Us-Later

ClinicalTrials.gov lists NCT06075667 as a randomized study of once-weekly tirzepatide in adolescents ages 12 to 17 with obesity, or overweight plus a weight-related condition. It enrolled 160 participants. The registry marks primary completion on June 2, 2026, overall completion in July 2029, and status as active but not recruiting [2].

As of August 29, 2026, the registry says results are not posted [2]. Primary completion means the main endpoint data were collected; it does not mean the data have been publicly analyzed, peer reviewed, or added to the label. A future press release would also not substitute for the complete result tables, adverse-event denominators, attrition, subgroup limits, and FDA review.

Until those materials exist, this study cannot responsibly answer:

• which dose or escalation pace balances benefit and tolerability in adolescents;
• whether growth, pubertal development, bone health, or mental-health outcomes differ from control;
• how outcomes vary across age, sex, baseline BMI, or coexisting disease;
• what happens after treatment stops; or
• whether the benefit-risk assessment supports a pediatric indication.

The page will need a dated evidence update when results or a labeling decision appear. "Trial completed" is not a dosing instruction.

Why SURPASS-PEDS Does Not Fill the Obesity Gap

SURPASS-PEDS was a randomized phase 3 trial of tirzepatide in young people ages 10 to under 18 with type 2 diabetes [3]. It matters because it supplies pediatric exposure and outcome data for tirzepatide. Its lead author, Tamara S. Hannon, MD, and colleagues studied a different clinical question, population, endpoint set, and dose context from Zepbound treatment of adolescent obesity.

Brand names do not change the active ingredient, but indications and evidence still matter. A diabetes trial cannot be relabeled as a Zepbound obesity trial. It also cannot validate claims that adolescent weight loss will match adult SURMOUNT-1 results or exceed semaglutide results. Cross-trial comparisons would mix age groups, conditions, designs, doses, and endpoints.

If Off-Label Use Is Being Discussed

FDA labeling does not replace a clinician's full legal and clinical analysis of off-label prescribing. It does establish what the sponsor has demonstrated for the approved product. For a patient under 18, the conversation should begin with the absence of a Zepbound pediatric indication and dose-not with an adult schedule presented as settled.

Use this question record to make the uncertainty inspectable:

This is not a checklist that authorizes treatment. It is a way to detect when an off-label proposal depends on extrapolation rather than adolescent evidence.

Safety Topics Without Inventing a Teen Protocol

The adult Zepbound label describes gastrointestinal reactions, volume-depletion kidney injury, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia with insulin or an insulin secretagogue, and other warnings [1]. Those risks should not be hidden. They also do not establish teen-specific rates or a universal pediatric testing schedule.

The label does not require a baseline TSH for every patient, routine calcitonin screening, DEXA at fixed intervals, a specific protein target, or PHQ screening at months 1, 3, and 6. Some of those evaluations may be appropriate because of an individual's history, another guideline, or a pediatric specialist's plan. Presenting them as Zepbound requirements would be false precision.

The FDA announced in January 2026 that its comprehensive review did not find an increased risk of suicidal behavior or ideation with GLP-1 receptor agonist medicines and asked manufacturers to remove that warning from affected weight-management labels [6]. The February Zepbound label records that removal [1]. Mental health still matters in adolescent obesity care; the point is to use current evidence rather than repeat an obsolete class-warning claim.

Suspected overdose or an accidental extra injection is not an age-adjustment question. Use the Zepbound dose-error guide and contact Poison Help or a qualified clinician rather than calculating a home dose threshold.

Approved Alternatives Are a Separate Comparison

The AAP guideline supports offering weight-loss pharmacotherapy to eligible adolescents age 12 and older as an adjunct to health behavior and lifestyle treatment [4]. It does not say that every adult obesity medicine has a pediatric indication.

Wegovy's current FDA label includes patients age 12 and older with obesity [5]. That makes it a relevant approved-option discussion, but not an automatic choice and not evidence that Zepbound should use Wegovy's dosing. The Wegovy pediatric page owns that product-specific evidence.

The useful comparison is not "which adult trial lost more weight?" It is:

• Is the product approved for this age and condition?
• What adolescent trial directly supports it?
• Which outcomes and harms were measured?
• How closely does the patient resemble the study population?
• Which uncertainties remain after approval?

Bottom Line

There is no FDA-approved Zepbound dose for adolescents. The adult schedule should not be republished as a teen protocol, and the completed-but-unreported adolescent obesity trial cannot yet supply one. SURPASS-PEDS adds pediatric tirzepatide evidence for type 2 diabetes, not Zepbound adolescent-obesity approval. A responsible page should preserve that distinction until public results and a regulator decision change it.